0001437749-22-025632.txt : 20221103 0001437749-22-025632.hdr.sgml : 20221103 20221103061058 ACCESSION NUMBER: 0001437749-22-025632 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20221101 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20221103 DATE AS OF CHANGE: 20221103 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOLARGO, INC. CENTRAL INDEX KEY: 0000880242 STANDARD INDUSTRIAL CLASSIFICATION: CHEMICALS & ALLIED PRODUCTS [2800] IRS NUMBER: 650159115 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19709 FILM NUMBER: 221356005 BUSINESS ADDRESS: STREET 1: 14921 CHESTNUT ST. CITY: WESTMINSTER STATE: CA ZIP: 92683 BUSINESS PHONE: 888 400-2863 MAIL ADDRESS: STREET 1: 14921 CHESTNUT ST. CITY: WESTMINSTER STATE: CA ZIP: 92683 FORMER COMPANY: FORMER CONFORMED NAME: NUWAY MEDICAL INC DATE OF NAME CHANGE: 20030205 FORMER COMPANY: FORMER CONFORMED NAME: NUWAY ENERGY INC DATE OF NAME CHANGE: 20010815 FORMER COMPANY: FORMER CONFORMED NAME: LATIN AMERICAN CASINOS INC DATE OF NAME CHANGE: 19960520 8-K 1 blgo20221102_8k.htm FORM 8-K blgo20221102_8k.htm
false 0000880242 0000880242 2022-11-01 2022-11-01
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 8-K
 
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
 
Date of Report (Date of earliest event reported): November 1, 2022
 
BioLargo, Inc.
(Exact name of registrant as specified in its charter)
 
Delaware
 
000-19709
 
65-0159115
(State or other jurisdiction
of incorporation)
 
(Commission File Number)
 
(IRS Employer
Identification No.)
 
 
14921 Chestnut St., Westminster, California
 
92683
(Address of principal executive offices)
 
(Zip Code)
 
Registrant’s telephone number, including area code: (888) 400-2863
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b))
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock
BLGO
OTCQB
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 

 
 
Item 5.02          Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
 
On November 1, 2022, the Board of Directors of BioLargo, Inc. (“BioLargo) accepted the resignations of board members John S. Runyan and Kent C. Roberts II, and appointed Linda Park and Christina Bray to the board. Each of Ms. Park and Ms. Bray were appointed to the Audit Committee, Compensation Committee, and Nomination and Corporate Governance Committee. BioLargo entered into agreements with each of Ms. Park and Ms. Bray for compensation for their services as board members, which includes the issuance of options to purchase 100,000 shares of stock at the closing price of BioLargo’s common stock on November 1, 2022, which was $0.244, and the payment of quarterly board fees of $15,000, payable through the issuance of options to purchase common stock, priced at the closing price of the BioLargo’s common stock as of the last trading day of each quarter, in accordance with the company’s normal practices. The agreements are effective as of November 1, 2022, and terminate upon the director’s removal from the board in accordance with the company’s articles or bylaws, or should the director not be re-elected at the annual stockholders meeting. The agreements require the directors keep information confidential, and each acknowledged receipt of the company’s Insider Trading policy.
 
Additionally, BioLargo entered into indemnity agreements each of Ms. Park and Ms. Bray, requiring BioLargo hold harmless and indemnify each director to the fullest extent permitted by law.
 
Item 7.01 Regulation FD Disclosure.
 
On November 3, 2022, BioLargo, Inc. published the press release which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
 
The information in this Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 7.01 and in the press release attached as Exhibit 99.1 to this Current Report shall not be incorporated by reference into any filing with the SEC made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The Company undertakes no duty or obligation to update or revise the information contained in this report, although it may do so from time to time as its management believes is appropriate. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosures. For important information about forward looking statements, see the information under the heading “Safe Harbor Act” in Exhibit 99.1 attached hereto.
 
Item 9.01. Financial Statements and Exhibits.
 
(d)         Exhibits.
 
   
Exhibit No.
Description
10.1
10.2
99.1
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
                 
Date: November 3, 2022
     
BIOLARGO, INC.
         
           
By:
 
/s/ Dennis P. Calvert
               
Dennis P. Calvert
               
President and Chief Executive Officer
 
 
 
EX-10.1 2 ex_441688.htm EXHIBIT 10.1 ex_441688.htm
 

Exhibit 10.1

 

[FORM OF] BOARD OF DIRECTORS AGREEMENT

(INDEPENDENT DIRECTORS)

 

THIS AGREEMENT is made by and between BioLargo, Inc., a Delaware corporation (the “Company”) with its principal place of business located at 14921 Chestnut Street, Westminster, CA 92683, and ____________________________________, an individual (“Director”).

 

1.    Effective Date

 

This Agreement shall commence as of the date Director is appointed or elected to the Company’s Board of Directors (“Effective Date”) and shall continue thereafter so long as Director is reelected as a member of the Board of Directors by the stockholders of the Company at the annual stockholder meeting, or this Agreement is terminated as set forth in Section 4 below.

 

2.    Position and Responsibilities

 

a.    Position. The Board of Directors hereby appoints the Director to serve as a Board Member until the next annual meeting of the Company’s stockholders or until his/her earlier resignation, removal or death. The Director shall perform such duties and responsibilities as are customarily related to such position in accordance with Company’s bylaws and applicable law, including, but not limited to, those services described on Exhibit A attached hereto (the “Services”).  Director hereby agrees to use his/her best efforts to provide the Services.  Director shall not allow any other person or entity to perform any of the Services for or instead of Director.  Director shall comply with the statutes, rules, regulations and orders of any governmental or quasi-governmental authority, which are applicable to the Company and the performance of the Services, including without limitation Delaware law, and Company’s rules, regulations, and practices as they may from time-to-time be adopted or modified.

 

b.    Other Activities. Director may be employed by another company, may serve on other boards of directors or advisory boards, and may engage in any other business activity (whether or not pursued for pecuniary advantage), as long as such outside activities do not violate Director’s obligations under this Agreement or Director’s fiduciary obligations to the Company or its stockholders. The ownership of less than a 5% interest in an entity, by itself, shall not constitute a violation of this duty. Director represents that Director has no outstanding agreement or obligation that is in conflict with any of the provisions of this Agreement, and Director agrees to use her best efforts to avoid or minimize any such conflict and agrees not to enter into any agreement or obligation that could create such a conflict without the approval of a majority of the Board of Directors. If, at any time, Director is required to make any disclosure or take any action that may conflict with any of the provisions of this Agreement, Director will promptly notify the Board of such obligation, prior to making such disclosure or taking such action.

 

c.    No Conflict. Director will not engage in any activity that creates an actual or perceived conflict of interest with Company, regardless of whether such activity is prohibited by Company’s conflict of interest guidelines or this Agreement, and Director agrees to notify the Board of Directors before engaging in any activity that could reasonably be assumed to create a potential conflict of interest with Company. Notwithstanding the provisions of Section 2(b) hereof, Director shall not engage in any activity that is in direct competition with the Company or serve in any capacity (including, but not limited to, as an employee, consultant, advisor or director) in any company or entity that competes directly or indirectly with the Company, as reasonably determined by a majority of Company’s disinterested board members, without the approval of the Board of Directors.

 

- 1 -

 

3.    Compensation and Benefits for Non-Employee Directors

 

a.    Initial Stock Option Award. Company shall issue to Director an option to purchase 100,000 shares of commons stock (the “Option”), at an exercise price equal to the closing price of the Company’s common stock as the effective date hereof, issued pursuant to the Company’s 2018 Equity Incentive Plan. The Option shall vest at the rate of 25% per quarter, beginning January 1, 2023.

 

b.    Quarterly Fee. In consideration of the services to be rendered under this Agreement, and provided Director is not an employee of the Company, Company shall pay Director an quarterly fee at the rate of $15,000.00 per quarter, which shall be paid in accordance with Company’s regularly established practices regarding the payment of Directors’ fees, which may include the issuance of options to purchase the Company’s common stock in lieu of cash payment.

 

c.    Committee Chairs. The chair of any Board committee receives an additional $3,750 in compensation per quarter, paid as set forth in subparagraph (a) above.

 

d.    Expenses. The Company shall reimburse Director for all reasonable business expenses incurred in the performance of the Services in accordance with Company’s expense reimbursement guidelines.

 

e.    Indemnification; Insurance. Company will indemnify and defend Director against any liability incurred in the performance of the Services in accordance with an Indemnity Agreement entered into concurrent with this Agreement. Company has in place, and will continue to keep in place in subsequent policy years, Director’s and Officer’s liability insurance. Director shall be entitled to the protection of any insurance policies the Company maintains for the benefit of its Directors and Officers against all costs, charges and expenses in connection with any action, suit or proceeding to which she may be made a party by reason of her affiliation with Company, its subsidiaries, or affiliates.

 

f.    Records. So long as the Director shall serve as a member of the Company’s Board of Directors, Director shall have full access to books and records of Company and access to management personnel of the Company.

 

4.    Termination

 

a.    Right to Terminate. At any time, Director may be removed as a Board Member as provided in Company’s Articles of Incorporation, as amended, bylaws, as amended, and applicable law. Director may resign as Board Member as provided in Company’s Articles of Incorporation, as amended, bylaws, as amended, and applicable law. Notwithstanding anything to the contrary contained in or arising from this Agreement or any statements, policies, or practices of Company, neither Director nor Company shall be required to provide any advance notice or any reason or cause for termination of Director’s status as Board Member, except as provided in Company’s Articles of Incorporation, as amended, Company’s bylaws, as amended, and applicable law.

 

- 2 -

 

b.    Automatic Termination. This Agreement shall automatically terminate if Director is not re-elected to the Company’s board of directors by the stockholders at the annual stockholders meeting.

 

c.    Effect of Termination as Director. Upon Director’s termination this Agreement will terminate; Company shall pay to Director all compensation and expenses to which Director is entitled up through the date of termination; and Director shall be entitled to her rights under any other applicable law. Thereafter, all of Company’s obligations under this Agreement shall cease.

 

5.    Termination Obligations

 

a.    Director agrees that all property, including, without limitation, all equipment, tangible proprietary information, documents, records, notes, contracts, and computer-generated materials provided to or prepared by Director incident to the Services and her membership on the Company’s Board of Directors or any committee therefore is the sole and exclusive property of the Company and shall be promptly returned to the Company at such time as the Director is no longer a member of the Company’s Board of Directors.

 

b.    Upon termination of this Agreement, Director shall be deemed to have resigned from all offices and committee memberships then held with Company by virtue of her position as Board Member. Director agrees that following any termination of this Agreement, she shall cooperate with Company in the winding up or transferring to other directors of any pending work and shall also cooperate with Company (to the extent allowed by law, and at Company’s expense) in the defense of any action brought by any third party against Company that relates to the Services.

 

6.    Nondisclosure Obligations

 

Director shall maintain in confidence and shall not, directly or indirectly, disclose or use, either during or after the term of this Agreement, any Proprietary Information (as defined below), confidential information, or trade secrets belonging to Company, whether or not it is in written or permanent form, except to the extent necessary to perform the Services, as required by a lawful government order or subpoena, or as authorized in writing by Company. These nondisclosure obligations also apply to Proprietary Information belonging to customers and suppliers of Company, and other third parties, learned by Director as a result of performing the Services. “Proprietary Information” means all information pertaining in any manner to the business of Company, unless (i) the information is or becomes publicly known through lawful means; (ii) the information was part of Director’s general knowledge prior to her relationship with Company; or (iii) the information is disclosed to Director without restriction by a third party who rightfully possesses the information and did not learn of it from Company.

 

- 3 -

 

7.    Insider Trading

 

Director acknowledges receipt of, and agrees to abide by, the Company’s insider trading policy.

 

8.    Dispute Resolution

 

a.    Jurisdiction and Venue. The parties agree that any suit, action, or proceeding between Director and Company (and its affiliates, stockholders, directors, officers, employees, members, agents, successors, attorneys, and assigns) relating to this Agreement shall be brought in the County of Orange, California, either the United States District Court or a California state court, and that the parties shall submit to the jurisdiction of such court. The parties irrevocably waive, to the fullest extent permitted by law, any objection the party may have to the laying of venue for any such suit, action or proceeding brought in such court. If any one or more provisions of this Section shall for any reason be held invalid or unenforceable, it is the specific intent of the parties that such provisions shall be modified to the minimum extent necessary to make it or its application valid and enforceable.

 

b.    Attorneys Fees. Should any litigation, arbitration or other proceeding be commenced between the parties concerning the rights or obligations of the parties under this Agreement, the party prevailing in such proceeding shall be entitled, in addition to such other relief as may be granted, to a reasonable sum as and for its attorneys’ fees in such proceeding. This amount shall be determined by the court in such proceeding or in a separate action brought for that purpose. In addition to any amount received as attorneys’ fees, the prevailing party also shall be entitled to receive from the party held to be liable, an amount equal to the attorneys’ fees and costs incurred in enforcing any judgment against such party. This Section is severable from the other provisions of this Agreement and survives any judgment and is not deemed merged into any judgment.

 

9.    Entire Agreement

 

This Agreement constitutes the entire understanding between the parties hereto superseding all prior and contemporaneous agreements or understandings among the parties hereto concerning the Agreement.

 

10.    Amendments; Waivers

 

This Agreement may be amended, modified, superseded or canceled, and any of the terms, covenants, representations, warranties or conditions hereof may be waived, only by a written instrument executed by the parties or, in the case of a waiver, by the party to be charged.  Any amendment or waiver by the Company must be approved by the Company’s Board of Directors and executed on behalf of the Company by its Chief Executive Officer.  If the Director shall also serve as Chief Executive Officer, such amendment or waiver must be executed on behalf of the Company by an officer designed by the Company’s Board of Directors.

 

- 4 -

 

11.    Assignment

 

This Agreement shall not be assignable by either party.

 

12.    Severability

 

If any provision of this Agreement shall be held by a court to be invalid, unenforceable, or void, such provision shall be enforced to fullest extent permitted by law, and the remainder of this Agreement shall remain in full force and effect. In the event that the time period or scope of any provision is declared by a court of competent jurisdiction to exceed the maximum time period or scope that such court deems enforceable, then such court shall reduce the time period or scope to the maximum time period or scope permitted by law.

 

13.    Governing Law

 

This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware.

 

14.    Interpretation

 

This Agreement shall be construed as a whole, according to its fair meaning, and not in favor of or against any party. Captions are used for reference purposes only and should be ignored in the interpretation of the Agreement.

 

15.    Binding Agreement

 

Each party represents and warrants to the other that the person(s) signing this Agreement below has authority to bind the party to this Agreement and that this Agreement will legally bind both Company and Director. To the extent that the practices, policies, or procedures of Company, now or in the future, are inconsistent with the terms of this Agreement, the provisions of this Agreement shall control. Any subsequent change in Director’s duties or compensation as Board Member will not affect the validity or scope of the remainder of this Agreement.

 

16.    Director Acknowledgment

 

Director acknowledges Director has had the opportunity to consult legal counsel concerning this Agreement, that Director has read and understands the Agreement, that Director is fully aware of its legal effect, and that Director has entered into it freely based on her own judgment and not on any representations or promises other than those contained in this Agreement.

 

17.    Counterparts

 

This Agreement may be executed in any number of counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

 

[SIGNATURE PAGE FOLLOWS]

 

- 5 -

 

 

IN WITNESS WHEREOF, the Parties have executed this Board Member Agreement as of the date set forth above.

 

BioLargo, Inc.   Board Member
     

 

 

 

By: Dennis P. Calvert

President/CEO

 

Name: ____________________________

 

- 6 -

 

 

EXHIBIT A

 

DESCRIPTION OF SERVICES

 

Responsibilities as Director. Director shall have all responsibilities of a Director of the Company imposed by Delaware or applicable law, the Articles of Incorporation, as amended, and Bylaws, as amended, of Company. These responsibilities shall include, but shall not be limited to, the following:

 

 

1.

Attendance. Use best efforts to attend scheduled meetings of Company’s Board of Directors;

 

 

2.

Act as a Fiduciary. Represent the stockholders and the interests of Company as a fiduciary;

 

 

3.

Participation. Participate as a full voting member of Company’s Board of Directors in setting overall objectives, approving plans and programs of operation, formulating general policies, offering advice and counsel, serving on Board Committees, and reviewing management performance; and

 

 

4.

Board committees. Participate on committees of the Board of Directors as appointed by the Board of Directors, using best efforts to attend scheduled committee meetings and ensure performance of the committee as set forth in the committee charter.

 

 

 

- 7 -
EX-10.2 3 ex_441689.htm EXHIBIT 10.2 ex_441689.htm

Exhibit 10.2

 

INDEMNIFICATION AGREEMENT

 

THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of November 1, 2022, by and between BioLargo, Inc., a Delaware corporation (the “Company”), and _____________________ (“Indemnitee”).

 

WITNESSETH THAT:

 

WHEREAS, highly competent persons have become more reluctant to serve corporations as directors or in other capacities unless they are provided with adequate protection through insurance or adequate indemnification against inordinate risks of claims and actions against them arising out of their service to and activities on behalf of the corporation;

 

WHEREAS, the Board of Directors of the Company (the “Board”) has determined that, in order to attract and retain qualified individuals, the Company will attempt to maintain on an ongoing basis, at its sole expense, liability insurance to protect persons serving the Company and its subsidiaries from certain liabilities. Although the furnishing of such insurance has been a customary and widespread practice among United States‑based corporations and other business enterprises, the Company believes that, given current market conditions and trends, such insurance may be available to it in the future only at higher premiums and with more exclusions. At the same time, directors, officers, and other persons in service to corporations or business enterprises are being increasingly subjected to expensive and time‑consuming litigation relating to, among other things, matters that traditionally would have been brought only against the Company or business enterprise itself. The Bylaws and Articles of Incorporation of the Company require indemnification of the officers and directors of the Company. Indemnitee may also be entitled to indemnification pursuant to the General Corporation Law of the State of Delaware (“GCL”). The Bylaws and Articles of Incorporation and the GCL contemplate that contracts may be entered into between the Company and members of the Board, officers and other persons with respect to indemnification;

 

WHEREAS, the uncertainties relating to such insurance and to indemnification have increased the difficulty of attracting and retaining such persons;

 

WHEREAS, the Board has determined that the increased difficulty in attracting and retaining such persons is detrimental to the best interests of the Company’s shareholders and that the Company should act to assure such persons that there will be increased certainty of such protection in the future;

 

WHEREAS, it is reasonable, prudent and necessary for the Company contractually to obligate itself to indemnify, and to advance expenses on behalf of, such persons to the fullest extent permitted by applicable law so that they will serve or continue to serve the Company free from undue concern that they will not be so indemnified;

 

WHEREAS, this Agreement is a supplement to and in furtherance of the Bylaws and Articles of Incorporation of the Company and any resolutions adopted pursuant thereto, and shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder; and

 

WHEREAS, Indemnitee does not regard the protection available under the Company’s Bylaws and Articles of Incorporation and insurance as adequate in the present circumstances, and may not be willing to serve as an officer or director without adequate protection, and the Company desires Indemnitee to serve in such capacity. Indemnitee is willing to serve, continue to serve and to take on additional service for or on behalf of the Company on the condition that he be so indemnified.

 

 

 

 

NOW, THEREFORE, in consideration of Indemnitee’s agreement to serve as a director from and after the date hereof, the parties hereto agree as follows:

 

1.     Indemnity of Indemnitee. The Company hereby agrees to hold harmless and indemnify Indemnitee to the fullest extent permitted by law, as such may be amended from time to time. In furtherance of the foregoing indemnification, and without limiting the generality thereof.

 

(a)    Proceedings Other Than Proceedings by or in the Right of the Company. Indemnitee shall be entitled to the rights of indemnification provided in this Section l(a) if, by reason of his Corporate Status (as hereinafter defined), the Indemnitee is, or is threatened to be made, a party to or participant in any Proceeding (as hereinafter defined) other than a Proceeding by or in the right of the Company. Pursuant to this Section 1(a), Indemnitee shall be indemnified against all Expenses (as hereinafter defined), judgments, penalties, fines and amounts paid in settlement actually and reasonably incurred by him, or on his behalf, in connection with such Proceeding or any claim, issue or matter therein, if the Indemnitee acted in good faith and in a manner the Indemnitee reasonably believed to be in or not opposed to the best interests of the Company, and with respect to any criminal Proceeding, had no reasonable cause to believe the Indemnitee’s conduct was unlawful.

 

(b)    Proceedings by or in the Right of the Company. Indemnitee shall be entitled to the rights of indemnification provided in this Section 1(b) if, by reason of his Corporate Status, the Indemnitee is, or is threatened to be made, a party to or participant in any Proceeding brought by or in the right of the Company. Pursuant to this Section 1(b), Indemnitee shall be indemnified against all Expenses actually and reasonably incurred by the Indemnitee, or on the Indemnitee’s behalf, in connection with such Proceeding if the Indemnitee acted in good faith and in a manner the Indemnitee reasonably believed to be in or not opposed to the best interests of the Company; provided, however, if applicable law so provides, no indemnification against such Expenses shall be made in respect of any claim, issue or matter in such Proceeding as to which Indemnitee shall have been adjudged to be liable to the Company unless and to the extent that a court of competent jurisdiction in the State of California shall determine that such indemnification may be made.

 

(c)    Indemnification for Expenses of a Party Who is Wholly or Partly Successful. Notwithstanding any other provision of this Agreement, to the extent that Indemnitee is, by reason of his Corporate Status, a party to and is successful, on the merits or otherwise, in any Proceeding, he shall be indemnified to the maximum extent permitted by law, as such may be amended from time to time, against all Expenses actually and reasonably incurred by him or on his behalf in connection therewith. If Indemnitee is not wholly successful in such Proceeding but is successful, on the merits or otherwise, as to one or more but less than all claims, issues or matters in such Proceeding, the Company shall indemnify Indemnitee against all Expenses actually and reasonably incurred by him or on his behalf in connection with each successfully resolved claim, issue or matter. For purposes of this Section and without limitation, the termination of any claim, issue or matter in such a Proceeding by dismissal, with or without prejudice, shall be deemed to be a successful result as to such claim, issue or matter.

 

2.    Additional Indemnity. In addition to, and without regard to any limitations on, the indemnification provided for in Section 1 of this Agreement, the Company shall and hereby does indemnify and hold harmless Indemnitee against all Expenses, judgments, penalties, fines and amounts paid in settlement actually and reasonably incurred by him or on his behalf if, by reason of his Corporate Status, he is, or is threatened to be made, a party to or participant in any Proceeding (including a Proceeding by or in the right of the Company), including, without limitation, all liability arising out of the negligence or active or passive wrongdoing of Indemnitee. The only limitation that shall exist upon the Company’s obligations pursuant to this Agreement shall be that the Company shall not be obligated to make any payment to Indemnitee that is finally determined (under the procedures, and subject to the presumptions, set forth in Sections 6 and 7 hereof) to be unlawful.

 

- 2 -

 

3.    Contribution.

 

(a)    Whether or not the indemnification provided in Sections 1 and 2 hereof is available, in respect of any threatened, pending or completed action, suit or proceeding in which the Company is jointly liable with Indemnitee (or would be if joined in such action, suit or proceeding), the Company shall pay, in the first instance, the entire amount of any judgment or settlement of such action, suit or proceeding without requiring Indemnitee to contribute to such payment and the Company hereby waives and relinquishes any right of contribution it may have against Indemnitee. The Company shall not enter into any settlement of any action, suit or proceeding in which the Company is jointly liable with Indemnitee (or would be if joined in such action, suit or proceeding) unless such settlement provides for a full and final release of all claims asserted against Indemnitee.

 

(b)    Without diminishing or impairing the obligations of the Company set forth in the preceding subparagraph, if, for any reason, Indemnitee shall elect or be required to pay all or any portion of any judgment or settlement in any threatened, pending or completed action, suit or proceeding in which the Company is jointly liable with Indemnitee (or would be if joined in such action, suit or proceeding), the Company shall contribute to the amount of Expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred and paid or payable by Indemnitee in proportion to the relative benefits received by the Company and all officers, directors or employees of the Company, other than Indemnitee, who are jointly liable with Indemnitee (or would be if joined in such action, suit or proceeding), on the one hand, and Indemnitee, on the other hand, from the transaction or events from which such action, suit or proceeding arose; provided, however, that the proportion determined on the basis of relative benefit may, to the extent necessary to conform to law, be further adjusted by reference to the relative fault of the Company and all officers, directors or employees of the Company other than Indemnitee who are jointly liable with Indemnitee (or would be if joined in such action, suit or proceeding), on the one hand, and Indemnitee, on the other hand, in connection with the transaction or events that resulted in such expenses, judgments, fines or settlement amounts, as well as any other equitable considerations which applicable law may require to be considered. The relative fault of the Company and all officers, directors or employees of the Company, other than Indemnitee, who are jointly liable with Indemnitee (or would be if joined in such action, suit or proceeding), on the one hand, and Indemnitee, on the other hand, shall be determined by reference to, among other things, the degree to which their actions were motivated by intent to gain personal profit or advantage, the degree to which their liability is primary or secondary and the degree to which their conduct is active or passive.

 

(c)    The Company hereby agrees to fully indemnify and hold Indemnitee harmless from any claims of contribution which may be brought by officers, directors, or employees of the Company, other than Indemnitee, who may be jointly liable with Indemnitee.

 

(d)    To the fullest extent permissible under applicable law, if the indemnification provided for in this Agreement is unavailable to Indemnitee for any reason whatsoever, the Company, in lieu of indemnifying Indemnitee, shall contribute to the amount incurred by Indemnitee, whether for judgments, fines, penalties, excise taxes, amounts paid or to be paid in settlement and/or for Expenses, in connection with any claim relating to an indemnifiable event under this Agreement, in such proportion as is deemed fair and reasonable in light of all of the circumstances of such Proceeding in order to reflect (i) the relative benefits received by the Company and Indemnitee as a result of the event(s) and/or transaction(s) giving cause to such Proceeding and/or (ii) the relative fault of the Company (and its directors, officers, employees and agents) and Indemnitee in connection with such event(s) and/or transaction(s).

 

- 3 -

 

4.    Indemnification for Expenses of a Witness. Notwithstanding any other provision of this Agreement, to the extent that Indemnitee is, by reason of his Corporate Status, a witness, or is made (or asked) to respond to discovery requests, in any Proceeding to which Indemnitee is not a party, he shall be indemnified against all Expenses actually and reasonably incurred by him or on his behalf in connection therewith.

 

5.    Advancement of Expenses. Notwithstanding any other provision of this Agreement, the Company shall advance all Expenses incurred by or on behalf of Indemnitee in connection with any Proceeding by reason of Indemnitee’s Corporate Status within thirty (30) days after the receipt by the Company of a statement or statements from Indemnitee requesting such advance or advances from time to time, whether prior to or after final disposition of such Proceeding. Such statement or statements shall reasonably evidence the Expenses incurred by Indemnitee and shall include or be preceded or accompanied by a written undertaking by or on behalf of Indemnitee to repay any Expenses advanced if it shall ultimately be determined that Indemnitee is not entitled to be indemnified against such Expenses. Any advances and undertakings to repay pursuant to this Section 5 shall be unsecured and interest free.

 

6.    Procedures and Presumptions for Determination of Entitlement to Indemnification. It is the intent of this Agreement to secure for Indemnitee rights of indemnity that are as favorable as may be permitted under the GCL and public policy of the State of Delaware. Accordingly, the parties agree that the following procedures and presumptions shall apply in the event of any question as to whether Indemnitee is entitled to indemnification under this Agreement:

 

(a)    To obtain indemnification under this Agreement, Indemnitee shall submit to the Company a written request, including therein or therewith such documentation and information as is reasonably available to Indemnitee and is reasonably necessary to determine whether and to what extent Indemnitee is entitled to indemnification. The Secretary of the Company shall, promptly upon receipt of such a request for indemnification, advise the Board in writing that Indemnitee has requested indemnification. Notwithstanding the foregoing, any failure of Indemnitee to provide such a request to the Company, or to provide such a request in a timely fashion, shall not relieve the Company of any liability that it may have to Indemnitee unless, and to the extent that, such failure actually and materially prejudices the interests of the Company.

 

(b)    Upon written request by Indemnitee for indemnification pursuant to the first sentence of Section 6(a) hereof, a determination with respect to Indemnitee’s entitlement thereto shall be made in the specific case by one of the following four methods, which shall be at the election of the Board (1) by a majority vote of the disinterested directors, even though less than a quorum, (2) by a committee of disinterested directors designated by a majority vote of the disinterested directors, even though less than a quorum, (3) if there are no disinterested directors or if the disinterested directors so direct, by independent legal counsel in a written opinion to the Board, a copy of which shall be delivered to the Indemnitee, or (4) if so directed by the Board, by the shareholders of the Company. For purposes hereof, disinterested directors are those members of the Board who are not parties to the action, suit or proceeding in respect of which indemnification is sought by Indemnitee.

 

(c)    If the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to Section 6(b) hereof, the Independent Counsel shall be selected as provided in this Section 6(c). The Independent Counsel shall be selected by the Board. Indemnitee may, within ten (10) days after such written notice of selection was given, deliver to the Company a written objection to such selection; provided, however, that such objection may be asserted only on the ground that the Independent Counsel so selected does not meet the requirements of “Independent Counsel” as defined in Section 13 of this Agreement, and the objection shall set forth with particularity the factual basis of such assertion. Absent a proper and timely objection, the person so selected shall act as Independent Counsel. If a written objection is made and substantiated, the Independent Counsel selected may not serve as Independent Counsel unless and until such objection is withdrawn or a court has determined that such objection is without merit. If, within twenty (20) days after submission by Indemnitee of a written request for indemnification pursuant to Section 6(a) hereof, no Independent Counsel shall have been selected and not objected to, either the Company or Indemnitee may petition a court of competent jurisdiction in the State of California or other court of competent jurisdiction for resolution of any objection which shall have been made by the Indemnitee to the Company’s selection of Independent Counsel and/or for the appointment as Independent Counsel of a person selected by the court or by such other person as the court shall designate, and the person with respect to whom all objections are so resolved or the person so appointed shall act as Independent Counsel under Section 6(b) hereof. The Company shall pay any and all reasonable fees and expenses of Independent Counsel incurred by such Independent Counsel in connection with acting pursuant to Section 6(b) hereof, and the Company shall pay all reasonable fees and expenses incident to the procedures of this Section 6(c), regardless of the manner in which such Independent Counsel was selected or appointed.

 

- 4 -

 

(d)    In making a determination with respect to entitlement to indemnification hereunder, the person or persons or entity making such determination shall presume that Indemnitee is entitled to indemnification under this Agreement. Anyone seeking to overcome this presumption shall have the burden of proof and the burden of persuasion by clear and convincing evidence. Neither the failure of the Company (including by its directors or independent legal counsel) to have made a determination prior to the commencement of any action pursuant to this Agreement that indemnification is proper in the circumstances because Indemnitee has met the applicable standard of conduct, nor an actual determination by the Company (including by its directors or independent legal counsel) that Indemnitee has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that Indemnitee has not met the applicable standard of conduct.

 

(e)    Indemnitee shall be deemed to have acted in good faith if Indemnitee’s action is based on the records or books of account of the Enterprise (as hereinafter defined), including financial statements, or on information supplied to Indemnitee by the officers of the Enterprise in the course of their duties, or on the advice of legal counsel for the Enterprise or on information or records given or reports made to the Enterprise by an independent certified public accountant or by an appraiser or other expert selected with reasonable care by the Enterprise. In addition, the knowledge and/or actions, or failure to act, of any director, officer, agent or employee of the Enterprise shall not be imputed to Indemnitee for purposes of determining the right to indemnification under this Agreement. Whether or not the foregoing provisions of this Section 6(e) are satisfied, it shall in any event be presumed that Indemnitee has at all times acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the Company. Anyone seeking to overcome this presumption shall have the burden of proof and the burden of persuasion by clear and convincing evidence.

 

(f)    If the person, persons or entity empowered or selected under Section 6 to determine whether Indemnitee is entitled to indemnification shall not have made a determination within sixty (60) days after receipt by the Company of the request therefor, the requisite determination of entitlement to indemnification shall be deemed to have been made and Indemnitee shall be entitled to such indemnification absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee’s statement not materially misleading, in connection with the request for indemnification, or (ii) a prohibition of such indemnification under applicable law; provided, however, that such sixty (60) day period may be extended for a reasonable time, not to exceed an additional thirty (30) days, if the person, persons or entity making such determination with respect to entitlement to indemnification in good faith requires such additional time to obtain or evaluate documentation and/or information relating thereto; and provided further, that the foregoing provisions of this Section 6(f) shall not apply if the determination of entitlement to indemnification is to be made by the shareholders pursuant to Section 6(b) of this Agreement and if (A) within fifteen (15) days after receipt by the Company of the request for such determination, the Board or the Disinterested Directors, if appropriate, resolve to submit such determination to the shareholders for their consideration at an annual meeting thereof to be held within seventy five (75) days after such receipt and such determination is made thereat, or (B) a special meeting of shareholders is called within fifteen (15) days after such receipt for the purpose of making such determination, such meeting is held for such purpose within sixty (60) days after having been so called and such determination is made thereat.

 

- 5 -

 

(g)    Indemnitee shall cooperate with the person, persons or entity making such determination with respect to Indemnitee’s entitlement to indemnification, including providing to such person, persons or entity upon reasonable advance request any documentation or information which is not privileged or otherwise protected from disclosure and which is reasonably available to Indemnitee and reasonably necessary to such determination. Any Independent Counsel, member of the Board or shareholder of the Company shall act reasonably and in good faith in making a determination regarding the Indemnitee’s entitlement to indemnification under this Agreement. Any costs or expenses (including attorneys’ fees and disbursements) incurred by Indemnitee in so cooperating with the person, persons or entity making such determination shall be borne by the Company (irrespective of the determination as to Indemnitee’s entitlement to indemnification) and the Company hereby indemnifies and agrees to hold Indemnitee harmless therefrom.

 

(h)    The Company acknowledges that a settlement or other disposition short of final judgment may be successful if it permits a party to avoid expense, delay, distraction, disruption and uncertainty. In the event that any action, claim or proceeding to which Indemnitee is a party is resolved in any manner other than by adverse judgment against Indemnitee (including, without limitation, settlement of such action, claim or proceeding with or without payment of money or other consideration) it shall be presumed that Indemnitee has been successful on the merits or otherwise in such action, suit or proceeding. Anyone seeking to overcome this presumption shall have the burden of proof and the burden of persuasion by clear and convincing evidence.

 

(i)    The termination of any Proceeding or of any claim, issue or matter therein, by judgment, order, settlement or conviction, or upon a plea of nolo contendere or its equivalent, shall not (except as otherwise expressly provided in this Agreement) of itself adversely affect the right of Indemnitee to indemnification or create a presumption that Indemnitee did not act in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the Company or, with respect to any criminal Proceeding, that Indemnitee had reasonable cause to believe that his conduct was unlawful.

 

7.    Remedies of Indemnitee.

 

(a)    In the event that (i) a determination is made pursuant to Section 6 of this Agreement that Indemnitee is not entitled to indemnification under this Agreement, (ii) advancement of Expenses is not timely made pursuant to Section 5 of this Agreement, (iii) no determination of entitlement to indemnification is made pursuant to Section 6(b) of this Agreement within ninety (90) days after receipt by the Company of the request for indemnification, (iv) payment of indemnification is not made pursuant to this Agreement within ten (10) days after receipt by the Company of a written request therefor, or (v) payment of indemnification is not made within ten (10) days after a determination has been made that Indemnitee is entitled to indemnification or such determination is deemed to have been made pursuant to Section 6 of this Agreement, Indemnitee shall be entitled to an adjudication in an appropriate court of the State of California, or in any other court of competent jurisdiction, of Indemnitee’s entitlement to such indemnification. Indemnitee shall commence such proceeding seeking an adjudication within one hundred eighty (180) days following the date on which Indemnitee first has the right to commence such proceeding pursuant to this Section 7(a). The Company shall not oppose Indemnitee’s right to seek any such adjudication.

 

- 6 -

 

(b)    In the event that a determination shall have been made pursuant to Section 6(b) of this Agreement that Indemnitee is not entitled to indemnification, any judicial proceeding commenced pursuant to this Section 7 shall be conducted in all respects as a de novo trial on the merits, and Indemnitee shall not be prejudiced by reason of the adverse determination under Section 6(b).

 

(c)    If a determination shall have been made pursuant to Section 6(b) of this Agreement that Indemnitee is entitled to indemnification, the Company shall be bound by such determination in any judicial proceeding commenced pursuant to this Section 7, absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee’s misstatement not materially misleading in connection with the application for indemnification, or (ii) a prohibition of such indemnification under applicable law.

 

(d)    In the event that Indemnitee, pursuant to this Section 7, seeks a judicial adjudication of his rights under, or to recover damages for breach of, this Agreement, or to recover under any directors’ and officers’ liability insurance policies maintained by the Company, the Company shall pay on his behalf, in advance, any and all expenses (of the types described in the definition of Expenses in Section 12(d) of this Agreement) actually and reasonably incurred by him in such judicial adjudication, regardless of whether Indemnitee ultimately is determined to be entitled to such indemnification, advancement of expenses or insurance recovery.

 

(e)    The Company shall be precluded from asserting in any judicial proceeding commenced pursuant to this Section 7 that the procedures and presumptions of this Agreement are not valid, binding and enforceable and shall stipulate in any such court that the Company is bound by all the provisions of this Agreement. The Company shall indemnify Indemnitee against any and all Expenses and, if requested by Indemnitee, shall (within ten (10) days after receipt by the Company of a written request therefore) advance, to the extent not prohibited by law, such expenses to Indemnitee, which are incurred by Indemnitee in connection with any action brought by Indemnitee for indemnification or advance of Expenses from the Company under this Agreement or under any directors’ and officers’ liability insurance policies maintained by the Company, regardless of whether Indemnitee ultimately is determined to be entitled to such indemnification, advancement of Expenses or insurance recovery, as the case may be.

 

(f)    Notwithstanding anything in this Agreement to the contrary, no determination as to entitlement to indemnification under this Agreement shall be required to be made prior to the final disposition of the Proceeding.

 

8.    NonExclusivity; Survival of Rights; Insurance; Primacy of Indemnification; Subrogation.

 

(a)    The rights of indemnification as provided by this Agreement shall not be deemed exclusive of any other rights to which Indemnitee may at any time be entitled under applicable law, the Articles of Incorporation, the By‑laws, any agreement, a vote of shareholders, a resolution of directors of the Company, or otherwise. No amendment, alteration or repeal of this Agreement or of any provision hereof shall limit or restrict any right of Indemnitee under this Agreement in respect of any action taken or omitted by such Indemnitee in his Corporate Status prior to such amendment, alteration or repeal. To the extent that a change in the GCL, whether by statute or judicial decision, permits greater indemnification than would be afforded currently under the Articles of Incorporation, Bylaws and this Agreement, it is the intent of the parties hereto that Indemnitee shall enjoy by this Agreement the greater benefits so afforded by such change. No right or remedy herein conferred is intended to be exclusive of any other right or remedy, and every other right and remedy shall be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise. The assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any other right or remedy.

 

- 7 -

 

(b)    To the extent that the Company maintains an insurance policy or policies providing liability insurance for directors, officers, employees, or agents or fiduciaries of the Company or of any other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise that such person serves at the request of the Company, Indemnitee shall be covered by such policy or policies in accordance with its or their terms to the maximum extent of the coverage available for any director, officer, employee, agent or fiduciary under such policy or policies. If, at the time of the receipt of a notice of a claim pursuant to the terms hereof, the Company has directors’ and officers’ liability insurance in effect, the Company shall give prompt notice of the commencement of such proceeding to the insurers in accordance with the procedures set forth in the respective policies. The Company shall thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of the Indemnitee, all amounts payable as a result of such proceeding in accordance with the terms of such policies.

 

(c)    In the event of any payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee.

 

(d)    The Company shall not be liable under this Agreement to make any payment of amounts otherwise indemnifiable hereunder if and to the extent that Indemnitee has otherwise actually received such payment under any insurance policy, contract, agreement or otherwise.

 

(e)    The Company’s obligation to indemnify or advance Expenses hereunder to Indemnitee who is or was serving at the request of the Company as a director, officer, employee or agent of any other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise shall be reduced by any amount Indemnitee has actually received as indemnification or advancement of expenses from such other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise.

 

9.    Exception to Right of Indemnification. Notwithstanding any provision in this Agreement, the Company shall not be obligated under this Agreement to make any indemnity in connection with any claim made against Indemnitee:

 

(a)    for which payment has actually been made to or on behalf of Indemnitee under any insurance policy or other indemnity provision, except with respect to any excess beyond the amount paid under any insurance policy or other indemnity provision; or

 

(b)    for an accounting of profits made from the purchase and sale (or sale and purchase) by Indemnitee of securities of the Company within the meaning of Section 16(b) of the Securities Exchange Act of 1934, as amended, or similar provisions of state statutory law or common law; or

 

(c)    in connection with any Proceeding (or any part of any Proceeding) initiated by Indemnitee, including any Proceeding (or any part of any Proceeding) initiated by Indemnitee against the Company or its directors, officers, employees or other indemnitees, unless (i) the Board authorized the Proceeding (or any part of any Proceeding) prior to its initiation, or (ii) the Company provides the indemnification, in its sole discretion, pursuant to the powers vested in the Company under applicable law.

 

- 8 -

 

10.    Duration of Agreement. All agreements and obligations of the Company contained herein shall continue during the period Indemnitee is an officer or director of the Company (or is or was serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise) and shall continue thereafter so long as Indemnitee shall be subject to any Proceeding (or any proceeding commenced under Section 7 hereof) by reason of his Corporate Status, whether or not he is acting or serving in any such capacity at the time any liability or expense is incurred for which indemnification can be provided under this Agreement. This Agreement shall be binding upon and inure to the benefit of and be enforceable by the parties hereto and their respective successors (including any direct or indirect successor by purchase, merger, consolidation or otherwise to all or substantially all of the business or assets of the Company), assigns, spouses, heirs, executors and personal and legal representatives.

 

11.    Enforcement.

 

(a)    The Company expressly confirms and agrees that it has entered into this Agreement and assumes the obligations imposed on it hereby in order to induce Indemnitee to serve as an officer or director of the Company, and the Company acknowledges that Indemnitee is relying upon this Agreement in serving as an officer or director of the Company.

 

(b)    This Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter hereof and supersedes all prior agreements and understandings, oral, written and implied, between the parties hereto with respect to the subject matter hereof.

 

(c)    The Company shall not seek from a court, or agree to, a “bar order” which would have the effect of prohibiting or limiting the Indemnitee’s rights to receive advancement of expenses under this Agreement.

 

12.    Definitions. For purposes of this Agreement:

 

(a)    Corporate Status” describes the status of a person who is or was a director, officer, employee, agent or fiduciary of the Company or of any other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise that such person is or was serving at the express written request of the Company.

 

(b)    Disinterested Director” means a director of the Company who is not and was not a party to the Proceeding in respect of which indemnification is sought by Indemnitee.

 

(c)    Enterprise” shall mean the Company and any other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise that Indemnitee is or was serving at the express written request of the Company as a director, officer, employee, agent or fiduciary.

 

(d)    Expenses” shall include all reasonable attorneys’ fees, retainers, court costs, transcript costs, fees of experts, witness fees, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees and all other disbursements or expenses of the types customarily incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating, participating, or being or preparing to be a witness in a Proceeding, or responding to, or objecting to, a request to provide discovery in any Proceeding. Expenses also shall include Expenses incurred in connection with any appeal resulting from any Proceeding, including without limitation the premium, security for, and other costs relating to any cost bond, supersede as bond, or other appeal bond or its equivalent. Expenses, however, shall not include amounts paid in settlement by Indemnitee or the amount of judgments or fines against Indemnitee.

 

- 9 -

 

(e)    Independent Counsel” means a law firm, or a member of a law firm, that is experienced in matters of corporation law and neither presently is, nor in the past five years has been, retained to represent (i) the Company or Indemnitee in any matter material to either such party (other than with respect to matters concerning Indemnitee under this Agreement, or of other indemnitees under similar indemnification agreements), or (ii) any other party to the Proceeding giving rise to a claim for indemnification hereunder. Notwithstanding the foregoing, the term “Independent Counsel” shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an action to determine Indemnitee’s rights under this Agreement. The Company agrees to pay the reasonable fees of the Independent Counsel referred to above and to fully indemnify such counsel against any and all Expenses, claims, liabilities and damages arising out of or relating to this Agreement or its engagement pursuant hereto.

 

(f)    Proceeding” includes any threatened, pending or completed action, suit, arbitration, alternate dispute resolution mechanism, investigation, inquiry, administrative hearing or any other actual, threatened or completed proceeding, whether brought by or in the right of the Company or otherwise and whether civil, criminal, administrative or investigative, in which Indemnitee was, is or will be involved as a party or otherwise, by reason of his or her Corporate Status, by reason of any action taken by him or of any inaction on his part while acting in his or her Corporate Status; in each case whether or not he is acting or serving in any such capacity at the time any liability or expense is incurred for which indemnification can be provided under this Agreement; including one pending on or before the date of this Agreement, but excluding one initiated by an Indemnitee pursuant to Section 7 of this Agreement to enforce his rights under this Agreement.

 

13.    Severability. The invalidity or unenforceability of any provision hereof shall in no way affect the validity or enforceability of any other provision. Without limiting the generality of the foregoing, this Agreement is intended to confer upon Indemnitee indemnification rights to the fullest extent permitted by applicable laws. In the event any provision hereof conflicts with any applicable law, such provision shall be deemed modified, consistent with the aforementioned intent, to the extent necessary to resolve such conflict.

 

14.    Modification and Waiver. No supplement, modification, termination or amendment of this Agreement shall be binding unless executed in writing by both of the parties hereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions hereof (whether or not similar) nor shall such waiver constitute a continuing waiver.

 

15.    Notice By Indemnitee. Indemnitee agrees promptly to notify the Company in writing upon being served with or otherwise receiving any summons, citation, subpoena, complaint, indictment, information or other document relating to any Proceeding or matter which may be subject to indemnification covered hereunder. The failure to so notify the Company shall not relieve the Company of any obligation which it may have to Indemnitee under this Agreement or otherwise unless and only to the extent that such failure or delay materially prejudices the Company.

 

16.    Notices. All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given (a) upon personal delivery to the party to be notified, (b) when sent by confirmed electronic mail or facsimile if sent during normal business hours of the recipient, and if not so confirmed, then on the next business day, (c) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one (1) day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. All communications shall be sent to the addresses set forth below the parties’ signatures hereto or to such other address as may have been furnished to Indemnitee by the Company or to the Company by Indemnitee, as the case may be.

 

- 10 -

 

17.    Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

 

18.    Headings. The headings of the paragraphs of this Agreement are inserted for convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction thereof.

 

19.    Governing Law and Consent to Jurisdiction. This Agreement and the legal relations among the parties shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware, without regard to its conflict of laws rules. The Company and Indemnitee hereby irrevocably and unconditionally (i) agree that any action or proceeding arising out of or in connection with this Agreement shall be brought only in the state and federal courts in the State of California (the “California Court”), and not in any other state or federal court in the United States of America or any court in any other country, (ii) consent to submit to the exclusive jurisdiction of the California Court for purposes of any action or proceeding arising out of or in connection with this Agreement, (iii) waive any objection to the laying of venue of any such action or proceeding in the California Court, and (iv) waive, and agree not to plead or to make, any claim that any such action or proceeding brought in the California Court has been brought in an improper or inconvenient forum.

 

IN WITNESS WHEREOF, the parties hereto have executed this Indemnification Agreement on and as of the day and year first above written.

 

 

COMPANY

 

     
  BIOLARGO, INC.  

 

 

 

 

 

 

 

 

 

 

Dennis P. Calvert, President

 

     
     
  INDEMNITEE  
     
     
  Name:                                                                 

 

 

- 11 -
EX-99.1 4 ex_441690.htm EXHIBIT 99.1 ex_441690.htm

Exhibit 99.1

 

BioLargo Adds Linda Park and Christina Bray to Board of Directors

 

Westminster, CA – November 3, 2022 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, announced it has added two new board members to its team: Linda Park and Christina Bray. Both new board members have a background, education, and corporate experience that make them an ideal fit to advance BioLargo’s core organizational goals, and its vision to “make life better” through its cleantech products and services.

 

Linda Park is a trusted executive and legal professional with a proven track record of supporting and advising public companies. With corporate board and executive experience at billion-dollar corporations such as her current roles working with Edward Lifesciences in her capacity as Corporate Secretary, Senior Vice President and Associate General Counsel, and Board Member of the Edwards Lifesciences Foundation, and prior work with Western Digital Corporation, Linda brings over 20 years of experience advancing organizations’ corporate governance and strategic goals. She also has many years of experience advising issuer and investment banking clients on corporate and securities matters, mergers and acquisitions, bank financings and capital markets, including initial public offerings. She is also an active partner and thought leader on environmental, social, and corporate governance issues. Linda has an undergraduate degree from Johns Hopkins University, and a law degree from Duke University School of Law.

 

Christina Bray is a senior finance specialist, entrepreneur, and renewables specialist, and currently serves as the CEO and founder of Bluedot Energies, an innovative company that designs, builds, and manages electric vehicle charging stations for large-scale public and private applications. A rising star in green energy technologies, Christina has significant finance, capital projects, and corporate operation experience, having negotiated M&A activities and managed $1 billion in quarterly loan volume at the solar fintech company Sunlight Financial. She has extensive training including a master’s degree in Military History from Norwich University and an undergraduate degree in Middle Eastern Studies from Yale University. She is well-versed in middle eastern language and society.

 

“We are so pleased that Linda Park and Christina Bray have joined our Board of Directors,” said Dennis P. Calvert, BioLargo’s CEO. “Both have such significant experience in advancing innovative projects, as well as building and supporting successful companies. We know that they will make important contributions to our efforts to transform BioLargo into a cleantech juggernaut. With Linda and Christina on board, we couldn’t be more confident in the future for our company.”

 

Concurrently, board members John S. Runyan and Kent C. (Rick) Roberts II have retired from their positions on the Board of Directors where they served faithfully for over a decade. Both will remain as formal Advisors to the Board of Directors as their time permits.

 

Mr. Calvert commented, “John and Rick have made significant contributions to the company over the years, and we are thankful for their meaningful impact on the company. We look forward to working with them in the future in their roles as Advisors to the board.”

 

 

 

About BioLargo, Inc.

 

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative technologies in the cleantech space, including for PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our approach is to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. We have developed a number of key channel partnerships to support the reach of our products and services and maximize their commercial potential. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 90 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. See our website at www.BioLargo.com.

 

Contact Information

 

Dennis P. Calvert

 

President and CEO, BioLargo, Inc.

 

888-400-2863

 

Safe Harbor Act

 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding anticipated revenue and plans for future operations, and may be identified by words such as “we believe”. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of global and regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

 

 

 
EX-101.SCH 5 blgo-20221101.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink EX-101.DEF 6 blgo-20221101_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 7 blgo-20221101_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity [Domain] Legal Entity [Axis] Document Information [Line Items] Document Information [Table] Document, Type Document, Period End Date Entity, Registrant Name Entity, Incorporation, State or Country Code Entity, File Number Entity, Tax Identification Number Entity, Address, Address Line One Entity, Address, City or Town Entity, Address, State or Province Entity, Address, Postal Zip Code City Area Code Local Phone Number Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Trading Symbol Entity, Emerging Growth Company Amendment Flag Entity, Central Index Key EX-101.PRE 8 blgo-20221101_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 9 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Document And Entity Information
Nov. 01, 2022
Document Information [Line Items]  
Entity, Registrant Name BioLargo, Inc.
Document, Type 8-K
Document, Period End Date Nov. 01, 2022
Entity, Incorporation, State or Country Code DE
Entity, File Number 000-19709
Entity, Tax Identification Number 65-0159115
Entity, Address, Address Line One 14921 Chestnut St.
Entity, Address, City or Town Westminster
Entity, Address, State or Province CA
Entity, Address, Postal Zip Code 92683
City Area Code 888
Local Phone Number 400-2863
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol BLGO
Entity, Emerging Growth Company false
Amendment Flag false
Entity, Central Index Key 0000880242
XML 10 blgo20221102_8k_htm.xml IDEA: XBRL DOCUMENT 0000880242 2022-11-01 2022-11-01 false 0000880242 8-K 2022-11-01 BioLargo, Inc. DE 000-19709 65-0159115 14921 Chestnut St. Westminster CA 92683 888 400-2863 false false false false Common Stock BLGO false EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 21 1 false 0 0 false 0 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.blgo.com/20221101/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false All Reports Book All Reports blgo20221102_8k.htm blgo-20221101.xsd blgo-20221101_def.xml blgo-20221101_lab.xml blgo-20221101_pre.xml ex_441688.htm ex_441689.htm ex_441690.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "blgo20221102_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "local": [ "blgo-20221101_def.xml" ] }, "inline": { "local": [ "blgo20221102_8k.htm" ] }, "labelLink": { "local": [ "blgo-20221101_lab.xml" ] }, "presentationLink": { "local": [ "blgo-20221101_pre.xml" ] }, "schema": { "local": [ "blgo-20221101.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 21, "memberCustom": 0, "memberStandard": 0, "nsprefix": "blgo", "nsuri": "http://www.blgo.com/20221101", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "blgo20221102_8k.htm", "contextRef": "d20228K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "role": "http://www.blgo.com/20221101/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "blgo20221102_8k.htm", "contextRef": "d20228K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blgo.com/20221101/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blgo.com/20221101/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blgo.com/20221101/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document, Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blgo.com/20221101/role/statement-document-and-entity-information" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document, Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blgo.com/20221101/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity, Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blgo.com/20221101/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity, Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blgo.com/20221101/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity, Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blgo.com/20221101/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity, Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blgo.com/20221101/role/statement-document-and-entity-information" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity, Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blgo.com/20221101/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blgo.com/20221101/role/statement-document-and-entity-information" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity, Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blgo.com/20221101/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity, File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blgo.com/20221101/role/statement-document-and-entity-information" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity, Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blgo.com/20221101/role/statement-document-and-entity-information" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity, Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blgo.com/20221101/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity, Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blgo.com/20221101/role/statement-document-and-entity-information" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blgo.com/20221101/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blgo.com/20221101/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blgo.com/20221101/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blgo.com/20221101/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blgo.com/20221101/role/statement-document-and-entity-information" ], "xbrltype": "securityTitleItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blgo.com/20221101/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blgo.com/20221101/role/statement-document-and-entity-information" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blgo.com/20221101/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 17 0001437749-22-025632-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-22-025632-xbrl.zip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end